Faron Pharmaceuticals Oy
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FPHAF research report →
Price Chart
About the company
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical firm dedicated to drug discovery and development. The company is advancing a pipeline of proprietary drug candidates that harness immune modulation to address significant unmet medical needs, spanning immuno-oncology, organ protection, and regenerative medicine. Its principal product candidates include Traumakine, an intravenous interferon beta-1a therapy, which targets acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant procedures, and ischemia-reperfusion injury.
- CEO
- Markku Tapani Jalkanen
- IPO
- 2020
- Employees
- 40
- HQ
- Turku, FI
Get TickerSpark's AI analysis on FPHAF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $209.54M
- P/E
- -3.41
- PEG
- -1.91
- P/S
- 0.00
- P/B
- 5.73
- EV/EBITDA
- -3.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 476.49%
- ROIC
- -63.84%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,673
- Net Income
- $-25,920+99.9%
- EPS
- $-0.00+99.9%
- OCF Growth
- +3.5%
- FCF Growth
- +3.1%
- 52W High
- $3.30
- 52W Low
- $3.30
- 50D MA
- $3.30
- 200D MA
- $3.30
- Beta
- 0.18
- RSI (14)
- 100
- Avg Volume
- 0
No earnings-call transcripts are available for FPHAF yet.
- Free Float
- 53.2%
- Shares Outstanding
- 63.50M
- Float Shares
- 33.79M
Our FPHAF coverage
Recent articles, reports, and earnings notes.
No research on FPHAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FPHAF report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.